anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The relationship between the IL1B-511C>T (rs16944) polymorphism and the risk of developing hematologic malignancies remains controversial. Thus, we performed a meta-analysis to evaluate the association between IL1B-511C>T polymorphism and the risk of developing hematologic malignancies. A comprehensive search was conducted to identify all eligible studies on IL1B-511C>T polymorphism and hematologic malignancies. Twelve case-control studies, with 2,896 cases and 3,716 controls, were selected for the analysis. The overall data failed to indicate a significant association between IL1B-511C>T polymorphism and the risk of hematologic malignancies (OR:1.06, 95% Confidence Interval [CI]: 0.93-1.22). Moreover, non-significant associations were observed in a stratified analysis according to neoplasm type (multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma), ethnicity (European and Asian), and Hardy-Weinberg equilibrium. In summary, our results suggest that there is no association between the IL1B-511C>T polymorphism and the risk of hematologic malignancies. As such, further large-scale studies are needed to confirm our findings.
Etoricoxib (brand name Arcoxia worldwide; also Algix and Tauxib in Italy) is a new COX-2 selective inhibitor (approx. 106.0 times more selective for COX-2 inhibition over COX-1). Doses are 120 mg/day for acute pain. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Note that approved indications differ by country.

Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2). This reduces the generation of prostaglandins (PGs) from arachidonic acid. Among the different functions exerted by PGs, their role in the inflammation cascade should be highlighted. COX-2 selective inhibitor (aka "COXIB") showed less marked activity on type 1 cycloxigenase compared to traditional non-steroidal anti-inflammatory drugs (NSAID). This reduced activity is the cause of reduced gastrointestinal toxicity.

Quantitative sensory tests (QST) are techniques employed to measure the intensity of stimuli needed to produce specific sensory perceptions. They are used to evaluate a sensory detection threshold or other sensory responses from supra-threshold stimulation. The common physical stimuli are (i) touch-pressure, (ii) vibration, and (iii) coolness, warmth, cold pain, and heat pain. In QST, the subject must be able to comprehend what is being asked by the test, alert and not taking mind-altering medications, and not biased to a certain test outcome.
Leuconostoc species are regarded as important causes for many infections in immunocompromised patients. In this study, we assessed the characteristics of Leuconostoc spp. causing bacteremia in patients at our center. This observational analysis was conducted in the microbiology laboratory of a tertiary care center in northern India from July 2021 to July 2023. Patients in whom blood culture bottles were positive for Leuconostoc lactis were included in the study. Culture isolates were identified by MALDI-ToF MS as L. lactis and tested for antibiotic sensitivity results by Kirby-Bauer disk diffusion method. Demographic and clinical details were collected and analyzed. During the study period, 6,742 blood culture bottles flagged positive. Among these, L. lactis was isolated from 14 (0.21%) patients. The median patient age was 34 years. The male-to-female ratio was 2.5:1. All the patients with L. lactis bacteremia had an underlying condition leading to immunosuppression (e.g., carcinoma and chronic kidney disease). All the patients with L. lactis bacteremia had an intravascular device present at the time of bacteremia. All isolates in the study were sensitive to doxycycline, high level gentamicin, minocycline, ampicillin-sulbactam, and linezolid. Mortality was attributed to bacteremia by L. lactis in five patients. Appropriate and timely identification of the Leuconostoc species is important for the clinician to tailor regimens for the patients.
A database stores pre-calculated solutions each of which defines a radiation therapy treatment plan for a treatment volume associated with at least one target and at least one organ-at-risk. The pre-calculated solutions are divided into at least two groups each of which includes at least one pre-calculated solution. The pre-calculated solutions in a given group represent radiation therapy treatment plans which share a common beam configuration. A radiation therapy treatment plan (s c ) is established based on the pre-calculated solutions as follows. A first user interface receives operator commands specifying criteria for selecting radiation therapy treatment plans from the database, the criteria defining a set of parameters for the treatment volume. In particular, the operator commands jointly specify criteria for selecting radiation therapy treatment plans from more than one of the at least two groups. When establishing a solution, a preference function is applied on at least two pre-calculated solutions to establish one and only one solution as a radiation therapy treatment plan (s c ) meeting the criteria.
Disclosed is a method and a technique for allowing a nonprofessional to utilize professional-tailored software to carry out an analysis without the professional being present. In the preferred embodiment, a decision tree is provided having multiple levels of analysis, where each level includes plural rules for optional use. Each rule is selectable for use by the professional, and if selected, the rule has provisions for allowing the professional to assign a numerical value for comparison with the client data. In the preferred embodiment, the professional can enter into the levels of the decision tree how many of the selected rules must pass or fail before the level is considered as a pass or fail condition. Also, provisions are made in the software to provide a “refer” output, where the test results are indeterminate and the patient must be tested again while yet present at the test facility.  
     A nonprofessional can attend to all the patent testing to obtain medical data from the patient—in the form of digital data. The nonprofessional can then apply the digital data test results of the patient to the software decision tree. Since the rules of the software decision tree were tailored by the professional, the output of the software represents a professional analysis that was obtained by a nonprofessional.
Suppurative cervical lymphadenitis sometimes resolves with oral antibiotic treatment; however, many children are hospitalized for intravenous treatment due to lack of improvement. When there is no substantial improvement, the possibility of a liquefaction process is considered, and as a result, source control such as needle aspiration or open surgical drainage is recommended. We examined, among pediatric patients hospitalized with suppurative cervical lymphadenitis, clinical and laboratory predictors for invasive intervention that may lead to early imaging and intervention, hasten recovery, and shorten length of hospitalization. We compared laboratory and clinical characteristics of pediatric patients hospitalized with suppurative cervical lymphadenitis during 2010-2017, according to 3 treatments: needle aspiration (N = 54), open surgical drainage (N = 37), and conservative adequate antibiotic treatment only (N = 292). Physical indicators such as local erythema and fluctuation were found as predictors for invasive interventions in hospitalized pediatric patients diagnosed with suppurative cervical lymphadenitis. No significant associations were found between invasive interventions and laboratory parameters assessed in this study. Children who underwent interventions displayed a prolonged average length of hospitalization and received extended antibiotic treatment prior to hospital admission. In hospitalized pediatric patients diagnosed with suppurative cervical lymphadenitis, physical examination findings are the main predictive factors for invasive interventions. Consequently, when such straightforward clinical findings are observed in the context of insufficient improvement during antibiotic treatment, they should prompt consideration of invasive intervention.
The production of pharmaceutical dragees involves spraying the sugar, filler and polyethylene glycol suspension of Specification 968,443 on the cores rotating in a dragee-making kettle, allowing the cores to run round for a period without external influence, and drying the so-treated cores by a current of warm air, these three steps being repeated until the desired amount of coating, e.g. up to 1,5 times the weight of the cores, has been put on. The apparatus of Specification 968,442 is suitable for the process.  German Specification 1,000,569 also is referred to.ALSO:The production of pharmaceutical dragees involves spraying the sugar, filler and polyethylene glycol suspension of Specification 968,443 on cores rotating in a dragee-making kettle, allowing the cores to run round for a period without external influence and drying the so treated cores by a current of warm air, these three steps being repeated until the desired amount of coating, e.g. up to 15 times the weight of the cores has been put on.  The apparatus of Specification 968,442 is suitable for the process.
The invention belongs to the field of biological medicines, and relates to an anti-TIGIT-anti-PD-L1 bispecific antibody, a pharmaceutical composition and application thereof. In particular, the invention relates to a bispecific antibody comprising: a first protein functional region that targets TIGIT, and a second protein functional region that targets a target different from TIGIT (e.g., PD-L1); wherein: the first protein functional region is an anti-TIGIT antibody or antigen-binding fragment thereof; the heavy chain variable region of the anti-TIGIT antibody comprises HCDR1 with an amino acid sequence shown as SEQ ID NO. 10, HCDR2 with an amino acid sequence shown as SEQ ID NO. 11 and HCDR3 with an amino acid sequence shown as SEQ ID NO. 12; and the light chain variable region of the anti-TIGIT antibody comprises LCDR1 with an amino acid sequence shown as SEQ ID NO. 13, LCDR2 with an amino acid sequence shown as SEQ ID NO. 14 and LCDR3 with an amino acid sequence shown as SEQ ID NO. 15. The bispecific antibody provided by the invention has high affinity for TIGIT and PD-L1 double targets, and has a good application prospect.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to medicinal agents used for normalization of arterial blood pressure and methods of treatment of patients with hypertension. The agent comprises N-carbanoylmethyl-4-phenyl-2-pyrrolidome and pharmaceutically acceptable carriers being a single dose of an active component in drug is 0.125-0.500 g. Method of treatment of patients with hypertension involves administration of the above mentioned agent in the dose 0.125-1.0 g, 1-4 times per 24 h for 20-30 days. Invention provides normalization of arterial blood pressure without unpleasant senses, decreases the frequency of adverse effects in therapy carrying out. EFFECT: improved method of treatment, enhanced effectiveness of drug. 4 cl, 1 tbl
Background: The frequency of major cancer surgery in the elderly (≥80 years) has increased concomitantly with the rise in average age of the population. We assessed early postoperative mortality following hepato-pancreato-biliary (HPB) and gastrointestinal (GI) procedures for common malignancies stratified by age. Methods: The National Cancer Database (2004-2017) was queried for patients who underwent resection for GI (gastroesophageal and colorectal) or HPB (pancreatic adenocarcinoma, biliary tract, and primary liver) cancers. We compared early postoperative mortality (30 d and 90 d) stratified by age (65-79 vs ≥80 years) and procedure, and compared survival outcomes by age and operative vs nonoperative management. Results: A total of 709,358 patients were included. The 30-day mortality ranged from 1.8% to 5.8% among patients 65-79 years and from 3.2% to 12.4% among patients ≥80 years depending on procedure. The 90-day mortality ranged from 3.6% to 10.6% in patients 65-79 years compared to 8.4%-21.0% among patients ≥80 years. The overall 90-day mortality was 5.2% for patients 65-79 years and 12.0% for patients ≥80 years (P < .001). Age ≥80 was associated with worse survival among operatively managed patients with each upper GI, HPB, and lower GI malignancy relative to younger patients on multivariable analysis. However, operative management of patients ≥80 years was associated with improved survival relative to nonoperative management. Discussion: Elderly patients suffer higher postoperative mortality after major GI and HPB cancer surgery, but operative management is associated with improved survival among patients ≥80 years as compared to nonoperative management. These data are important to contextualize when counseling elderly patients on their treatment options for localized GI and HPB cancers.
SAIDs are characterized by long dormant periods with no or only minor clinical symptoms interrupted by febrile crises accompanied by serous and synovial membrane inflammation that spontaneously resolves. Over the last decades, more than 50 genes encoding key components of the innate immune system have been identified to be involved in the pathophysiology of SAIDs, with both germline and somatic mosaic variations. When disease-causing variations are identified, specific biotherapies are proposed depending on the involved gene and pathway. However, despite these scientific advances, most SAIDs (70%) are of unknown etiology, the diagnosis is made with significant delay, and no targeted therapy can be suggested. This project aims to generate specific understanding and develop strategies for SAID patients with unknown etiology. The investigators aim to advance our understanding of SAIDs pathophysiology, find the disease-causing gene variations and identify the involved cellular pathways that should accelerate correct diagnosis and personalize treatment.
PURPOSE:To provide an adenosinedeaminase inhibitor composed of 9-beta-D-ribofuranosylpurine. CONSTITUTION:9-beta-D-Ribofuranosylpurine has adenosinedeaminase inhibiting activity. It is administered preferably at a dose of 50-100mg/kg daily by oral administration or 10-25mg/kg by parenteral administration, e.g. injection. It can be mixed with additives such as binder, lubricant, dispersing agent, suspension agent, emulsifier, diluent, etc. and applied in the form of solution, suspension, powder, granules, capsule, or tablet. Adenosinedeaminase is an enzyme capable of forming inosine by deamination of adenosine. When adenosinearabinoside which is an antiviral agent is treated with the enzyme, it is converted to hypoxanthine arabinoside, and its antiviral acitivity is eliminated.
Participants enrolled in this study arm will ingest a 20mg tablet containing istradefylline. Four hours later, participants will receive acute intermittent hypoxia (AIH). Breathing and pinch strength will be tested prior to taking the medication, and then immediately before, 60 minutes and 120 minutes after AIH. Participants will breathe 15 episodes/session of acute low oxygen. Air concentrations will be monitored to ensure delivery of 1-minute episodes of low oxygen, with 2 minutes room-air intervals. Respiratory rate, oxygen saturation, heart rate/rhythm, and blood pressure will be monitored throughout the session.
Sepsis is a leading cause of mortality in intensive care units. Sepsis is associated with activation of the coagulation cascade and inflammation. The aim of this study was to identify coagulation-related genes in sepsis that may provide translational potential therapeutic targets. The datasets GSE28750, GSE95233, and GSE65682 were downloaded from the gene expression omnibus database. Consensus-weighted gene co-expression network analysis (WGCNA) was used to identify sepsis modules. Gene set enrichment analysis was used to identify genes enriched in the coagulation cascade. The value of hub-gene in immunological analysis was tested in the validation sets (GSE95233). The value of hub-gene in clinical prognosis was tested in the validation sets (GSE65582). One thousand one hundred seventy-six genes with high connectivity in the clinically significant module were identified as hub genes. Ten genes were found to be enriched in coagulation-related signaling pathways. C3AR1 was selected for further analysis. The immune infiltration analysis showed that lower expression of C3AR1 was associated with immune response in sepsis and could be an independent predictor of survival status in sepsis patients. Meanwhile, univariate and multivariate Cox analysis showed that C3AR1 had a significant correlation with survival. C3AR1 may become an effective biomarker for worse outcomes in sepsis patients associated with immune and coagulation cascade.
Traditionally, spinal cord stimulation (SCS) has been used for patients with chronic neuropathic pain following back surgery (a condition known as Failed Back Surgery Syndrome (FBSS)). Although the National Institute for Health and Care Excellence (NICE) also recommends SCS for chronic neuropathic pain without previous back surgery, clinical outcome data is much needed in this patient group. Conventionally, patients receiving SCS are provided with tonic stimulation settings (where they feel tingling and paraesthesia); however newer methods include high-density stimulation (HD) that provides higher energy allowing the voltage to be reduced to subthreshold parameters, hence minimizing the tingling and paraesthesia. HD stimulation is widely offered to patients with SCS as part of routine clinical practice, although no known studies have yet investigated HD settings in patients with neuropathic pain without previous spinal surgery. Therefore, the purpose of this study is to determine the effectiveness of HD settings in patients without previous spinal surgery undergoing SCS. 20 patients without previous spinal surgery who are deemed suitable for SCS as part of NICE guidelines 159 pathway will be recruited for the study.

All patients have a trial of SCS where they will be offered HD settings. If successful (\>50% improvement in pain scores) they will be offered permanent implant. Those patients whose pain does not improve with HD settings will be further offered conventional tonic stimulation for one more week. Those patients who do not respond to both tonic and HD settings will be excluded and will not have permanent implant. This will also allow us to investigate the patient's preference between the HD neurostimulator settings and conventional tonic settings. We will also investigate the response to these stimulator settings on health related quality of life. Patients will complete quality of life questionnaires at Baseline, 1-month, 3-months and 12-months post-implant.
Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received syntocinon at visit one and placebo at visit two. Syntocinon is 24 IU dose administered intranasally in spray form.
Giant basal cell carcinoma (GBCC) is a rare and more aggressive variant of basal cell carcinoma. We present a case of GBCC with an overview of the challenges it presents.A man in his 60s presented to the tertiary care unit with a history of an ulcer over the posterior aspect of his left heel for the past 1 year. Examination revealed an ulceroproliferative lesion of 10×8 cm on the posterior aspect of the left heel and lower Tendo-Achilles region. A wedge biopsy of the lesion was performed twice, which demonstrated basal cell carcinoma. The patient underwent excision of the lesion with 10 mm margins. A split-thickness skin graft was placed and secured over the resultant wound with the application of a negative pressure wound dressing.The correlation between tumour size and tumour behaviour is examined. Additionally, the significance of tumour location, width of margins, incidence recurrence or metastasis is also studied.
Up to 18% of reproductive-aged women experience chronic pain in the vulvar region during sexual intercourse. This chronic pain condition is called vulvodynia. The main subtype of this pain condition is provoked vestibulodynia (PVD), which is characterized by a sharp or burning pain at the vaginal opening when there is a pressure applied to the vulvar vestibule or attempting vaginal penetration. Women suffering from PVD suffer from sexual dysfunctions, psychological distress and worsened quality of life. The treatment options currently available are still quite limited and some women still experience pain despite undertaking all options available. We, therefore, proposed a randomized and controlled study to investigate the feasibility and acceptability of a dry needling treatment for women suffering from PVD. Women diagnosed with provoked vestibulodynia will be randomized into the dry needling group or the sham-needle group. Participants and evaluators will be blinded. The dry needling group will receive 6 sessions of real dry needling for 6 consecutive weeks. For the first three sessions, the dry needling/or sham techniques will be aimed at the muscles of the trunk, lower back, hips and SI joints. For the last 3 treatment sessions, the dry needling/or sham techniques will aimed at the pelvic floor muscles. The sham group will receive the same 6 sessions of sham needling for 6 consecutive weeks, using a validated sham-needle. Outcomes measures will be assessed at baseline and 2 weeks post-treatment and will include: feasibility (adherence to treatment, retention rates, adverse effects, recruitment rates and data on dry needling (needles, # of insertions, pain related) and acceptability variables. Secondary outcomes will include pain intensity during intercourse (numeric scale) and quality (McGill pain questionnaire), pain during palpation and pressure pain threshold (Pressure algometer), psychosexual variables (sexual distress and sexual function), change in pain catastrophizing, change in quality of life in domains associated with chronic pelvic pain (Pelvic Pain Impact questionnaire, severity of symptoms related to central sensitization), perceived improvement and satisfaction after the treatment as well as pelvic floor muscle stiffness (shearwave elastography and dynamometric speculum)and function (dynamometric speculum), blinding efficacy.
Severe traumatic bleeding may lead to extremely high mortality rates, and early intervention to stop bleeding plays as a critical role in saving lives. However, rapid hemostasis in deep non-compressible trauma using a highly water-absorbent hydrogel, combined with strong tissue adhesion and bionic procoagulant mechanism, remains a challenge. In this study, a DNA hydrogel (DNAgel) network composed of natural nucleic acids with rapid water absorption, high swelling and instant tissue adhesion is reported, like a band-aid to physically stop bleeding. The excellent swelling behavior and robust mechanical performance, meanwhile, enable the DNAgel band-aid to fill the defect cavity and exert pressure on the bleeding vessels, thereby achieving compression hemostasis for deep tissue bleeding sites. The neutrophil extracellular traps (NETs)-inspired DNAgel network also acts as an artificial DNA scaffold for erythrocytes to adhere and aggregate, and activates platelets, promoting coagulation cascade in a bionic way. The DNAgel achieves lower blood loss than commercial gelatin sponge (GS) in male rat trauma models. In vivo evaluation in a full-thickness skin incision model also demonstrates the ability of DNAgel for promoting wound healing. Overall, the DNAgel band-aid with great hemostatic capacity is a promising candidate for rapid hemostasis and wound healing.